Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients

HM. Eid, ML. Wright, NV. Anil Kumar, A. Qawasmeh, STS. Hassan, A. Mocan, SM. Nabavi, L. Rastrelli, AG. Atanasov, PS. Haddad,

. 2017 ; 8 (-) : 387. [pub] 20170630

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17032054

Metabolic syndrome is a cluster of three or more metabolic disorders including insulin resistance, obesity, and hyperlipidemia. Obesity has become the epidemic of the twenty-first century with more than 1.6 billion overweight adults. Due to the strong connection between obesity and type 2 diabetes, obesity has received wide attention with subsequent coining of the term "diabesity." Recent studies have identified unique contributions of the immensely diverse gut microbiota in the pathogenesis of obesity and diabetes. Several mechanisms have been proposed including altered glucose and fatty acid metabolism, hepatic fatty acid storage, and modulation of glucagon-like peptide (GLP)-1. Importantly, the relationship between unhealthy diet and a modified gut microbiota composition observed in diabetic or obese subjects has been recognized. Similarly, the role of diet rich in polyphenols and plant polysaccharides in modulating gut bacteria and its impact on diabetes and obesity have been the subject of investigation by several research groups. Gut microbiota are also responsible for the extensive metabolism of polyphenols thus modulating their biological activities. The aim of this review is to shed light on the composition of gut microbes, their health importance and how they can contribute to diseases as well as their modulation by polyphenols and polysaccharides to control obesity and diabetes. In addition, the role of microbiota in improving the oral bioavailability of polyphenols and hence in shaping their antidiabetic and antiobesity activities will be discussed.

Applied Biotechnology Research Center Baqiyatallah University of Medical SciencesTehran Iran

Department of Chemistry Manipal Institute of Technology Manipal UniversityManipal India

Department of Natural Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences BrnoBrno Czechia

Department of Pharmaceutical Botany Iuliu Hatieganu University of Medicine and PharmacyCluj Napoca Romania ICHAT and Institute for Life Sciences University of Agricultural Sciences and Veterinary MedicineCluj Napoca Romania

Dipartimento di Farmacia University of SalernoFisciano Italy

Faculty of Pharmacy Hebron UniversityHebron Palestine

Institute of Genetics and Animal Breeding Polish Academy of SciencesJastrzebiec Poland Department of Pharmacognosy University of ViennaVienna Austria Department of Vascular Biology and Thrombosis Research Center for Physiology and Pharmacology Medical University of ViennaVienna Austria

Natural Health Products and Metabolic Diseases Laboratory Department of Pharmacology and Physiology Université de MontréalMontréal QC Canada Canadian Institutes of Health Research Team in Aboriginal Antidiabetic MedicinesMontréal QC Canada

Natural Health Products and Metabolic Diseases Laboratory Department of Pharmacology and Physiology Université de MontréalMontréal QC Canada Canadian Institutes of Health Research Team in Aboriginal Antidiabetic MedicinesMontréal QC Canada Department of Pharmacognosy University of Beni SuefBeni Suef Egypt

Nell Hodgson Woodruff School of Nursing Emory UniversityAtlanta GA United States

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17032054
003      
CZ-PrNML
005      
20171030122845.0
007      
ta
008      
171025s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2017.00387 $2 doi
035    __
$a (PubMed)28713266
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Eid, Hoda M $u Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology and Physiology, Université de MontréalMontréal, QC, Canada. Canadian Institutes of Health Research Team in Aboriginal Antidiabetic MedicinesMontréal, QC, Canada. Department of Pharmacognosy, University of Beni-SuefBeni-Suef, Egypt.
245    10
$a Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients / $c HM. Eid, ML. Wright, NV. Anil Kumar, A. Qawasmeh, STS. Hassan, A. Mocan, SM. Nabavi, L. Rastrelli, AG. Atanasov, PS. Haddad,
520    9_
$a Metabolic syndrome is a cluster of three or more metabolic disorders including insulin resistance, obesity, and hyperlipidemia. Obesity has become the epidemic of the twenty-first century with more than 1.6 billion overweight adults. Due to the strong connection between obesity and type 2 diabetes, obesity has received wide attention with subsequent coining of the term "diabesity." Recent studies have identified unique contributions of the immensely diverse gut microbiota in the pathogenesis of obesity and diabetes. Several mechanisms have been proposed including altered glucose and fatty acid metabolism, hepatic fatty acid storage, and modulation of glucagon-like peptide (GLP)-1. Importantly, the relationship between unhealthy diet and a modified gut microbiota composition observed in diabetic or obese subjects has been recognized. Similarly, the role of diet rich in polyphenols and plant polysaccharides in modulating gut bacteria and its impact on diabetes and obesity have been the subject of investigation by several research groups. Gut microbiota are also responsible for the extensive metabolism of polyphenols thus modulating their biological activities. The aim of this review is to shed light on the composition of gut microbes, their health importance and how they can contribute to diseases as well as their modulation by polyphenols and polysaccharides to control obesity and diabetes. In addition, the role of microbiota in improving the oral bioavailability of polyphenols and hence in shaping their antidiabetic and antiobesity activities will be discussed.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Wright, Michelle L $u Nell Hodgson Woodruff School of Nursing, Emory UniversityAtlanta, GA, United States.
700    1_
$a Anil Kumar, N V $u Department of Chemistry, Manipal Institute of Technology, Manipal UniversityManipal, India. $7 gn_A_00007054
700    1_
$a Qawasmeh, Abdel $u Faculty of Pharmacy, Hebron UniversityHebron, Palestine.
700    1_
$a Hassan, Sherif T S $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences BrnoBrno, Czechia.
700    1_
$a Mocan, Andrei $u Department of Pharmaceutical Botany, Iuliu Hatieganu University of Medicine and PharmacyCluj-Napoca, Romania. ICHAT and Institute for Life Sciences, University of Agricultural Sciences and Veterinary MedicineCluj-Napoca, Romania.
700    1_
$a Nabavi, Seyed M $u Applied Biotechnology Research Center, Baqiyatallah University of Medical SciencesTehran, Iran.
700    1_
$a Rastrelli, Luca $u Dipartimento di Farmacia, University of SalernoFisciano, Italy.
700    1_
$a Atanasov, Atanas G $u Institute of Genetics and Animal Breeding, Polish Academy of SciencesJastrzebiec, Poland. Department of Pharmacognosy, University of ViennaVienna, Austria. Department of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of ViennaVienna, Austria. $7 gn_A_00009691
700    1_
$a Haddad, Pierre S $u Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology and Physiology, Université de MontréalMontréal, QC, Canada. Canadian Institutes of Health Research Team in Aboriginal Antidiabetic MedicinesMontréal, QC, Canada.
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 8, č. - (2017), s. 387
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28713266 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030122932 $b ABA008
999    __
$a ind $b bmc $g 1255647 $s 993081
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c - $d 387 $e 20170630 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...